Trinity Capital announced the commitment of $12 million in growth capital to Delphinus Medical Technologies, Inc. ("Delphinus"), a medical imaging company that has developed SoftVue™, a dense breast screening innovation that increases cancer detection and decreases unnecessary call backs, while delivering a comfortable patient experience.

The SoftVue™ 3D Whole Breast Ultrasound Tomography System was approved by the U.S. Food & Drug Administration (FDA) in October 2021. This disruptive technology not only redefines the standards for early breast cancer detection but also enhances patient comfort, with 95% of women who have experienced SoftVue indicating they would recommend the exam to other women. Delphinus continues to expand its commercial foundation and most recently added Corewell Health as a commercial site to build a robust dense breast screening program to benefit patients.

"We are excited to be a part of Delphinus' journey as they innovate life-saving medical imaging technology," said Lauren Cosentino, Managing Director, Life Sciences at Trinity. "We believe in their team and are excited to help accelerate their growth trajectory."

This growth capital will enable the team at Delphinus to continue to scale operations and broaden their impact in the global healthcare community.

"Mammography is not enough to address the screening needs of dense breast patients," said Mark J Forchette, President and CEO of Delphinus Medical Technologies. "The addition of SoftVue for dense breast screening implements a comprehensive solution for sites to transform the clinical experience of their patients. Our relationship with Trinity Capital helps us make impactful investments to help sites embrace this innovation and serve the unmet patient needs that SoftVue was designed to address. We are thrilled to work together."